FDA 483 - GlaxoSmithKline Biologicals - August 05, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
GlaxoSmithKline Biologicals in Singapore received a Form 483 for significant deviations in manufacturing sterile bulk drug substance. Observations included inadequate sterility testing procedures that deviated from their approved BLA, incomplete investigations into particle contamination and alarm system outages prior to product release, and a failure to timely submit a Biological Product Deviation Report for glass fragment contamination. These issues affected multiple batches of Hiberix drug product released to the U.S. market.
ID · a79cc271-e4bb-49fd-8611-358008b339d4